People | November 22, 2024
Strides Pharma Science appoints Dr. C. Muthulingam as Executive VP - R&D
Dr. Muthu was last associated with Mankind Pharma
Dr. Muthu was last associated with Mankind Pharma
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
Subscribe To Our Newsletter & Stay Updated
